Why the study?
Does bivalirudin reduce MACE and NACE compared to unfractionated heparin in male and female ACS patients undergoing invasive management?
Does bivalirudin reduce MACE and NACE compared to unfractionated heparin in male and female ACS patients undergoing invasive management?
Bivalirudin does not significantly reduce MACE or NACE compared to unfractionated heparin in either male or female patients with ACS undergoing invasive management.
Answers are grounded in this paper and cite their sources.
Bivalirudin confers no MACE/NACE benefit over UFH in ACS patients of either sex; reinforces UFH equivalence for invasive management.
In ACS patients, the rates of MACE and NACE were not significantly lower with bivalirudin than with UFH in both sexes. The rate of the composite of urgent TVR, definite ST, or NACE was not significantly lower with a post-PCI bivalirudin infusion than with no post-PCI infusion in both sexes.
No takes yet. Share an insight, caveat, or question.
Gargiulo et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: